Large pharmaceutical companies may benefit from more customers under the Affordable Care Act, but they still lobby for fewer regulations in order to reduce the cost of bringing a new drug to market.
Pfizer lobbied on issues relating to health care reform, patents, consumer protection and safety, drug abuse, Medicare, taxes, trade, among others.
Top Pharmaceutical Companies Lobbying in the Third Quarter:
Pfizer Inc. spent $2,380,000 - up from $1,530,000 in Q2.
Amgen USA Inc. spent $2,520,000 - up from $1,980,000 in Q2.
Eli Lilly & Co. spent $2,380,000 - up from $1,965,000 in Q2.
Merck & Co. Inc. spent $1,420,000 - up from $900,000 in Q2.
Sanofi US Services Inc. spent $1,310,000 - up from $700,000 in Q2.
Johnson & Johnson Services Inc. spent $1,280,000 - down from $1,360,000 in Q2.
GlaxoSmithKline spent $1,270,000 - up from $520,000 in Q2.
Novartis Corp. spent $1,560,000 - up from $1,100,000 in Q2.
Abbvie Inc. spent $1,180,000 - up from $630,000 in Q2.
Bayer Corp. spent $1,100,000 - down from $1,020,000 in Q2.
AstraZeneca Pharmaceuticals LP spent $970,000 - up from $460,000 in Q2.
Genentech Inc. spent $890,000 - down from $1,077,000 in Q2.
Teva Pharmaceuticals USA Inc. spent $810,000 - down from $820,000 in Q2.
Eisai Inc. spent $780,000 - up from $435,000 in Q2.
Abbott Laboratories spent $580,000 - up from $280,000 in Q2.
Bristol-Myers Squibb Co. spent $542,000 - down from $724,000 in Q2.
Emd Serono Inc. spent $530,000 - down from $670,000 in Q2.
Novo Nordisk Inc. spent $500,000 - down from $640,000 in Q2.
Boehringer Ingelheim Pharmaceuticals Inc. spent $490,000 - down from $730,000 in Q2.
Allergan spent $320,000 - up from $290,000 in Q2.
Also lobbying were:
Pharmaceutical Research & Manufacturers of America (PhRMA) spent $4,020,000 - down from $4,400,000 in Q2.
Generic Pharmaceutical Manufacturers Assn. spent $579,690 - up from $524,888 in Q2.